bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
6.15
-0.42 (-6.33%)
At close: Oct 1, 2026, 4:00 PM EDT
6.01
-0.13 (-2.20%)
Pre-market: Oct 2, 2026, 8:41 AM EDT
bioAffinity Technologies Revenue
bioAffinity Technologies had revenue of $1.51M in the quarter ending June 30, 2026, with 18.99% growth. This brings the company's revenue in the last twelve months to $5.90M, down -23.17% year-over-year. In the year 2025, bioAffinity Technologies had annual revenue of $6.16M, down -34.18%.
Revenue (ttm)
$5.90M
Revenue Growth
-23.17%
P/S Ratio
0.56
Revenue / Employee
$103,526
Employees
57
Market Cap
3.32M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.16M | -3.20M | -34.18% |
| Dec 31, 2024 | 9.36M | 6.83M | 269.68% |
| Dec 31, 2023 | 2.53M | 2.53M | 52,627.44% |
| Dec 31, 2022 | 4.80K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MDxHealth | 114.02M |
| Biodesix | 102.94M |
| Burning Rock Biotech | 73.70M |
| Exagen | 71.12M |
| XWELL | 28.28M |
| Precipio | 27.20M |
| Insight Molecular Diagnostics | 1.67M |
| Quantum Cyber | 537.08K |
BIAF News
- 2 days ago - BioAffinity, AvMEDICAL deliver joint exhibition of CyPath Lung - TheFly
- 2 days ago - bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL - Business Wire
- 3 days ago - bioAffinity Technologies Proxy statement: Proxy filing - Filings
- 10 days ago - BioAffinity to present clinical, veteran-focused data on CyPath Lung - TheFly
- 10 days ago - bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference - Business Wire
- 14 days ago - bioAffinity Technologies Inc trading resumes - TheFly
- 14 days ago - bioAffinity Technologies Inc trading halted, volatility trading pause - TheFly
- 15 days ago - BioAffinity Technologies announces grant of Hong Kong patent for CyPath Lung - TheFly